- Home
- OBA vs CTMX Comparison
OBA vs CTMX Comparison
Compare OBA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBA
- CTMX
- Stock Information
- Founded
- OBA 2024
- CTMX 2008
- Country
- OBA Canada
- CTMX United States
- Employees
- OBA N/A
- CTMX N/A
- Industry
- OBA
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- OBA
- CTMX Health Care
- Exchange
- OBA Nasdaq
- CTMX Nasdaq
- Market Cap
- OBA 314.7M
- CTMX 349.6M
- IPO Year
- OBA 2025
- CTMX 2015
- Fundamental
- Price
- OBA $9.94
- CTMX $1.99
- Analyst Decision
- OBA
- CTMX Strong Buy
- Analyst Count
- OBA 0
- CTMX 3
- Target Price
- OBA N/A
- CTMX $5.67
- AVG Volume (30 Days)
- OBA 110.2K
- CTMX 2.7M
- Earning Date
- OBA 01-01-0001
- CTMX 11-06-2025
- Dividend Yield
- OBA N/A
- CTMX N/A
- EPS Growth
- OBA N/A
- CTMX 263.20
- EPS
- OBA N/A
- CTMX 0.49
- Revenue
- OBA N/A
- CTMX $141,100,000.00
- Revenue This Year
- OBA N/A
- CTMX N/A
- Revenue Next Year
- OBA N/A
- CTMX N/A
- P/E Ratio
- OBA N/A
- CTMX $4.02
- Revenue Growth
- OBA N/A
- CTMX 18.01
- 52 Week Low
- OBA $9.93
- CTMX $0.40
- 52 Week High
- OBA $9.97
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- OBA N/A
- CTMX 43.94
- Support Level
- OBA N/A
- CTMX $2.04
- Resistance Level
- OBA N/A
- CTMX $2.16
- Average True Range (ATR)
- OBA 0.00
- CTMX 0.12
- MACD
- OBA 0.00
- CTMX 0.00
- Stochastic Oscillator
- OBA 0.00
- CTMX 18.42
About OBA Oxley Bridge Acquisition Limited Class A Ordinary Shares
Oxley Bridge Acquisition Ltd is a blank check company.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.